Nicotine as a potential neuroprotective agent for Parkinson's disease

M Quik, XA Perez, T Bordia - Movement disorders, 2012 - Wiley Online Library
Converging research efforts suggest that nicotine and other drugs that act at nicotinic
acetylcholine receptors (nAChRs) may be beneficial in the management of Parkinson's disease. …

Multiple roles for nicotine in Parkinson's disease

…, T Bordia, C Campos, XA Perez - Biochemical …, 2009 - Elsevier
There exists a remarkable diversity of neurotransmitter compounds in the striatum, a pivotal
brain region in the pathology of Parkinson's disease, a movement disorder characterized by …

Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human α-synuclein in mice

EL Unger, DJ Eve, XA Perez, DK Reichenbach… - Neurobiology of …, 2006 - Elsevier
Genetic and biochemical abnormalities associated with α-synuclein are implicated in the
etiology of Parkinson's disease (PD). In this study, altered locomotor behavior linked to the …

Nicotine neuroprotection against nigrostriatal damage: importance of the animal model

M Quik, M O'Neill, XA Perez - Trends in pharmacological sciences, 2007 - cell.com
Parkinson's disease is a neurodegenerative movement disorder that is characterized by a loss
of nigrostriatal dopamine-containing neurons. Unexpectedly, there is a reduced incidence …

Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias

T Bordia, XA Perez, JE Heiss, D Zhang, M Quik - Neurobiology of disease, 2016 - Elsevier
L-dopa-induced dyskinesias (LIDs) are a serious complication of L-dopa therapy for Parkinson's
disease. Emerging evidence indicates that the nicotinic cholinergic system plays a role …

Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders

M Quik, XA Perez, SR Grady - Biochemical pharmacology, 2011 - Elsevier
Although a relative newcomer to the nicotinic acetylcholine receptor (nAChR) family,
substantial evidence suggests that α6 containing nAChRs play a key role in CNS function. This …

Nicotine and nicotinic receptor drugs: potential for Parkinson's disease and drug-induced movement disorders

M Quik, T Bordia, D Zhang, XA Perez - International review of neurobiology, 2015 - Elsevier
Parkinson's disease is a progressive neurodegenerative disorder associated with tremor,
rigidity, and bradykinesia, as well as nonmotor symptoms including autonomic impairments, …

Role for the nicotinic cholinergic system in movement disorders; therapeutic implications

M Quik, D Zhang, XA Perez, T Bordia - Pharmacology & therapeutics, 2014 - Elsevier
A large body of evidence using experimental animal models shows that the nicotinic cholinergic
system is involved in the control of movement under physiological conditions. This work …

Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice

XA Perez, D Zhang, T Bordia, M Quik - Movement Disorders, 2017 - Wiley Online Library
Background Dyskinesias are a disabling motor complication that arises with prolonged l‐dopa
treatment. Studies using D1 receptor drugs and genetically modified mice suggest that …

Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter

AB Manning-Boğ, WM Caudle, XA Perez… - Neurobiology of …, 2007 - Elsevier
Mutations in the gene for DJ-1 have been associated with early-onset autosomal recessive
parkinsonism. Previous studies of null DJ-1 mice have shown alterations in striatal dopamine …